HuGE Literature Finder
Records
1
-
8
Representation of CYP3A4, CYP3A5 and UGT1A4 Polymorphisms within Croatian Breast Cancer Patients' Population. International journal of environmental research and public health 2020 May 17 (10): . Bojanic Kristina, Kuna Lucija, Bilic Curcic Ines, Wagner Jasenka, Smolic Robert, Kralik Kristina, Kizivat Tomislav, Ivanac Gordana, Vcev Aleksandar, Wu George Y, Smolic Marti |
Association between ESR1, ESR2, HER2, UGT1A4, and UGT2B7 polymorphisms and breast Cancer in Jordan: a case-control study. BMC cancer 2019 Dec 19 (1): 1257. Al-Eitan Laith N, Rababa'h Doaa M, Alghamdi Mansour A, Khasawneh Rame |
The Effect of Polymorphism in UGT1A4 on Clinical Outcomes of Adjuvant Tamoxifen Therapy for Patients With Breast Cancer in China. Clinical breast cancer 2018 Dec . Lan Bo, Ma Fei, Han Mei, Chen Shanshan, Wang Wenna, Li Qiao, Fan Ying, Luo Yang, Cai Ruigang, Wang Jiayu, Yuan Peng, Zhang Pin, Li Qing, Xu Bing |
Pharmacogenetics of UGT1A4, UGT2B7 and UGT2B15 and Their Influence on Tamoxifen Disposition in Asian Breast Cancer Patients. Clinical pharmacokinetics 2016 Apr . Sutiman Natalia, Lim Joanne Siok Liu, Muerdter Thomas E, Singh Onkar, Cheung Yin Bun, Ng Raymond Chee Hui, Yap Yoon Sim, Wong Nan Soon, Ang Peter Cher Siang, Dent Rebecca, Schroth Werner, Schwab Matthias, Khor Chiea Chuen, Chowbay Balr |
Effect of MRP2 and MRP3 Polymorphisms on Anastrozole Glucuronidation and MRP2 and MRP3 Gene Expression in Normal Liver Samples. International journal of cancer research and molecular mechanisms 2015 Oct 1 (3): . Edavana Vineetha Koroth, Penney Rosalind B, Yao-Borengasser Aiwei, Starlard-Davenport Athena, Dhakal Ishwori B, Kadlubar Sus |
Impacts of the Glucuronidase Genotypes UGT1A4, UGT2B7, UGT2B15 and UGT2B17 on Tamoxifen Metabolism in Breast Cancer Patients. PloS one 2015 10 (7): e0132269. Romero-Lorca Alicia, Novillo Apolonia, Gaibar María, Bandrés Fernando, Fernández-Santander A |
Potential role of UGT1A4 promoter SNPs in anastrozole pharmacogenomics. Drug metabolism and disposition: the biological fate of chemicals 2013 Feb . Edavana VK, Dhakal IB, Williams S, Penney RB, Boysen G, Yao-Borengasser A, Kadlubar S |
Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma. Clinical pharmacology and therapeutics 2011 May 89 (5): 708-17. Mürdter T E, Schroth W, Bacchus-Gerybadze L, Winter S, Heinkele G, Simon W, Fasching P A, Fehm T, , Eichelbaum M, Schwab M, Brauch |
- Page last reviewed:Feb 1, 2023
- Page last updated:Mar 31, 2023
- Content source: